Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials
- 1 March 2000
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 14 (3), 356-363
- https://doi.org/10.1038/sj.leu.2401704
Abstract
Treatment of children with acute lymphoblastic leukaemia (ALL) aims to cure all patients with as little toxicity as possible and, if possible, to restrict further intensification of chemotherapy to patients with an increased risk of relapse. However in Medical Research Council (MRC) trial UKALL X two short myeloablative blocks of intensification therapy given at weeks 5 and 20 were of benefit to children in all risk groups. The successor trials, MRC UKALL XI and MRC ALL97, tested whether further intensification would continue to benefit all patients by randomising them to receive, or not, an extended third intensification block at week 35. After a median follow-up of 4 years (range 5 months to 8 years), 5 year projected event-free survival was superior at 68% for the 894 patients allocated a third intensification compared with 60% for the 887 patients who did not receive one (odds ratio 0.75, 95% CI 0.63–0.90, 2P = 0.002). This difference was almost entirely due to a reduced incidence of bone marrow relapses in the third intensification arm (140 of 891 in the third intensification arm vs 171 of 883 in the no third intensification, 2P = 0.02). Subgroup analysis suggests benefit of the third intensification for all risk categories. Overall survival to date is no different in the two arms, indicating that a greater proportion of those not receiving a third intensification arm and subsequently relapsing can be salvaged. These results indicate that there is benefit of additional intensification for all risk subgroups of childhood ALL.Keywords
This publication has 18 references indexed in Scilit:
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL XBritish Journal of Haematology, 1997
- Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials*British Journal of Haematology, 1995
- Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL XThe Lancet, 1995
- 9 Long-term sequelae of therapy for childhood acute lymphoblastic leukaemiaBailliere's Clinical Haematology, 1994
- Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of inductionThe Lancet, 1994
- Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research HospitalNew England Journal of Medicine, 1993
- Allocation of patients to treatment groups in a controlled clinical studyBritish Journal of Cancer, 1978
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977